Background: Carboplatin is a platinum coordination compound. Carboplatin, like cisplatin, produces predominantly interstrand DNA cross-links rather than DNA-protein cross-links. This effect is apparently cell-cycle nonspecific. The aquation of carboplatin, which is thought to produce the active species, occurs at a slower rate than in the case of cisplatin. The carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents.
Objectives: The purpose of this study is to investigate the appropriateness and rationality of carboplatin. Indications and renal function have been assessed to understand the appropriateness and rationality in a regional hospital in central Taiwan.
Methods: We gathered operable, taking carboplatin cancer patients from January 2019 to December 2019. A total of 261 cases received carboplatin. Patients diagnosed with ovarian cancers were considered as appropriate use of carboplatin. Patients whose creatinine clearance (CCr) lower than 60 mL/min were considered as rational use of carboplatin.
Results: A total of 261 patients received carboplatin in the year 2019. Sixty-four (64) patients diagnosed with ovarian cancer. The suggested dose for an ovarian cancer patient is 300 mg/m2-600 mg/m2The dosage ranges from 140 mg to 810 mg according to patients’ body surface area (BSA) and physical condition. There were one hundred and thirty-eight (138) patients whose creatinine clearance lower than 60 mL/min were not ovarian cancers. The suggestion dose for patient with CCR < 60 mL/min is 200 mg/m2-250 mg/m2. The dosage ranges from 100 mg to 400 mg according to patients’ conditions. The supplied doses for these two groups of patients were considered as appropriateness and rationality. The appropriateness rate was 77.4% in total. There were fifty-nine (59) patients who received carboplatin without indications.
Conclusions: The US FDA-approved indication for carboplatin in advanced ovarian cancer. In this review, the appropriate use of carboplatin was only 77.4%. The adverse events of carboplatin compared to cisplatin were worsened in bone marrow suppression. The carboplatin induces more severe bone marrow suppression reactions, related to receiving a dose, including thrombocytopenia, neutropenia, leukopenia, and anemia. However, the effects of renal function insufficient of carboplatin are better than cisplatin. Therefore, healthcare professionals may need to pay more attention to the use of carboplatin to avoid severe adverse events.
